BioSpace News Archive

An upsurge in the number of hospital-acquired diseases such as pneumonia and other oral infections has created a growth opportunity for manufacturers of disposable oral care devices. The global disposable oral care products market is set to surpass a valuation of US$ 4 Bn by 2029, as suggested by a new Persistence Market Research (PMR) study.

Endoscopic Submucosal Dissection (ESD) has witnessed slow adoption in Western countries in the past. This is due to the continued referral of patients for surgery or Endoscopic Mucosal Resection (EMR) procedures.

Adoption of miniaturized bioreactors is a growing trend, replacing conventional bioreactor systems in the life sciences industry. The introduction of miniaturized, disposable bioreactors and micro platforms is boosting the adoption of such devices for the production and testing of new pharmaceutical products.

According to a new study published by Persistence Market Research (PMR), the global human platelet lysate market is estimated to be valued at US$ 45.8 Mn in 2018 and is expected to expand at a CAGR of 3.6% over 2018–2026, to reach US$ 61.0 Mn by 2026 end.

As the COVID-19 pandemic continues to strain not just the physical and emotional well-being of front-line healthcare workers, many are also facing a financial burden and strain on their personal lives.

Fund will help team members with rent, groceries, dependent care and other needs

Arthritis Research Canada/Arthrite-recherche Canada is collaborating with the COVID-19 Global Rheumatology Alliance on an international initiative collecting information on rheumatology patients with COVID-19 from around the world.

InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,715,240 shares of its common stock at a purchase price of $1.75 per share in a registered direct offering priced at-the-market under Nasdaq rules

Protagonist Therapeutics, Inc. reported that on April 15, 2020, it issued an inducement award to Tracy Woody, the Company’s recently hired Executive Vice President of Corporate Strategy, in accordance with the terms of Ms. Woody’s employment offer letter.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to announce that Batavia Biosciences, its manufacturing partner for its preclinical candidate, IMP761, has made significant progress in the cell line development for the product candidate which is an immunosuppressive agonist antibody to LAG-3.